Encapsulation might boost remdesivir's safety profile


Remdesivir, an antiviral approved by the FDA to treat COVID-19, was also effective against Ebola and Middle East respiratory syndrome in tests with rhesus monkeys and Nipah virus infection in African green monkeys, but the drug had some adverse effects in humans that were not seen in nonhuman primate studies. Researchers found that the drug is unstable in plasma, but a new study posted on bioRxiv discovered that encapsulating remdesivir in a polymer boosted the drug's stability among healthy rats and rats infected with SARS-CoV-2.

Full story:

FBR SmartBrief

Biomedical research news.

FBR SmartBrief is a FREE, weekly e-mail newsletter. By providing the latest need-to-know industry news and information, FBR SmartBrief saves you time and keeps you smart.